Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) has announced it will present at the 2026 ThinkEquity Conference in New York, offering the clinical-stage pharmaceutical company direct access to institutional and accredited investors in the United States. The company's President and CEO will deliver a biotechnology track presentation covering its proprietary Energy-Activated Small Molecule (EASM) platform, including lead candidates Ruvidar® and Rutherrin®. The announcement comes as Theralase® prepares for regulatory review of its bladder cancer clinical data by Health Canada and the FDA, making investor visibility particularly timely.

Key Points

  • Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) is a Toronto-based clinical-stage pharmaceutical company
  • The company has been invited to present at the 2026 ThinkEquity Conference in New York across the biotechnology track
  • The conference is expected to feature 85 company presentations, more than 750 attendees, and more than 750 one-on-one investor meetings
  • Investors may be watching for updates on the Phase II bladder cancer study and regulatory strategy for Ruvidar® in Canada and the United States

Theralase® CEO to Outline EASM Platform and Clinical Programs in New York

Roger DuMoulin-White, President and Chief Executive Officer of Theralase®, will deliver the corporate presentation at the ThinkEquity Conference. The release states the presentation will cover the company's proprietary EASM technology platform, its ongoing clinical development programs, and upcoming corporate objectives. Management will also participate in scheduled one-on-one meetings with invited conference participants, providing an additional channel for direct engagement with the US investment community ahead of anticipated regulatory milestones.

Phase II Bladder Cancer Study and Ruvidar® Regulatory Strategy in Focus

A central element of the presentation is expected to be the Phase II clinical study evaluating intravesical light-activated Ruvidar® in patients diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. The presentation will also address Theralase®'s regulatory strategy for Ruvidar® in both Canada and the United States. The disclosure suggests the company views this conference as a strategic moment to communicate its commercialisation pathway to US-based investors as it approaches regulatory submissions.

Rutherrin® and Topical Ruvidar® Round Out the Pipeline Disclosure

Beyond bladder cancer, the conference presentation is expected to address the development of radiation-activated intravenous Rutherrin® for treatment of Glioblastoma Multiforme, Non-Small Cell Lung Cancer, and Muscle Invasive Bladder Cancer. The company also intends to discuss topical Ruvidar® for the treatment of Herpes Simplex Virus Type 1 cold sores. These programs illustrate the breadth of the EASM platform across oncology and infectious disease indications. The immediate share price impact was not clear from available public information.